Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 155,085,008
  • Shares Outstanding, K 1,240,680
  • Annual Sales, $ 28,754 M
  • Annual Income, $ 480,000 K
  • EBIT $ 10,490 M
  • EBITDA $ 13,257 M
  • 60-Month Beta 0.32
  • Price/Sales 5.35
  • Price/Cash Flow 18.04
  • Price/Book 7.17

Options Overview Details

View History
  • Implied Volatility 24.70% (-1.05%)
  • Historical Volatility 23.88%
  • IV Percentile 23%
  • IV Rank 14.26%
  • IV High 49.97% on 04/08/25
  • IV Low 20.50% on 01/08/25
  • Expected Move (DTE 8) 3.15 (2.56%)
  • Put/Call Vol Ratio 0.80
  • Today's Volume 6,891
  • Volume Avg (30-Day) 8,958
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 173,398
  • Open Int (30-Day) 206,006
  • Expected Range 119.48 to 125.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.86
  • Number of Estimates 6
  • High Estimate 1.96
  • Low Estimate 1.80
  • Prior Year 1.90
  • Growth Rate Est. (year over year) -2.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.13 +4.69%
on 11/10/25
128.70 -4.72%
on 11/20/25
-0.38 (-0.31%)
since 11/04/25
3-Month
108.46 +13.06%
on 10/02/25
128.70 -4.72%
on 11/20/25
+9.85 (+8.73%)
since 09/04/25
52-Week
88.57 +38.44%
on 01/10/25
128.70 -4.72%
on 11/20/25
+31.03 (+33.88%)
since 12/04/24

Most Recent Stories

More News
3 Unpopular Stocks We Think Twice About

3 Unpopular Stocks We Think Twice About

LSTR : 140.68 (+1.27%)
FDX : 274.05 (+1.33%)
GILD : 122.62 (-1.90%)
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

NVDA : 183.38 (+2.11%)
XLV : 153.90 (-0.76%)
JNJ : 202.48 (-1.39%)
LLY : 1,014.49 (-1.85%)
IBB : 172.11 (-0.07%)
GILD : 122.62 (-1.90%)
REGN : 722.80 (-0.12%)
AMGN : 340.16 (-1.52%)
UNH : 333.49 (-1.83%)
Is Gilead Sciences Stock Outperforming the Dow?

Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.

XLV : 153.90 (-0.76%)
$DOWI : 47,850.94 (-0.07%)
GILD : 122.62 (-1.90%)
BMY : 51.95 (+1.94%)
Gilead Foundation Commits Over $3 Million to Address Food Insecurity

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. –

GILD : 122.62 (-1.90%)
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million...

GILD : 122.62 (-1.90%)
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa

GILD : 122.62 (-1.90%)
1 Healthcare Stock to Own for Decades and 2 We Avoid

1 Healthcare Stock to Own for Decades and 2 We Avoid

SOLV : 85.26 (+0.01%)
COR : 337.63 (+0.69%)
GILD : 122.62 (-1.90%)
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – ...

GILD : 122.62 (-1.90%)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 465.34 (-1.68%)
EXEL : 44.37 (+0.82%)
GILD : 122.62 (-1.90%)
INSM : 205.04 (-0.84%)
UTHR : 484.10 (+0.65%)
Stocks Settle Mostly Higher on Government Reopening Optimism

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%. December E-mini...

AMAT : 269.44 (+0.30%)
AVGO : 381.03 (+0.11%)
MRK : 100.89 (-1.35%)
RGTI : 30.06 (+15.44%)
$IUXX : 25,581.70 (-0.10%)
AMGN : 340.16 (-1.52%)
PFE : 25.70 (+0.51%)
ELV : 333.49 (+0.83%)
ASML : 1,110.08 (-2.70%)
ZNH26 : 112-260 (+0.08%)
CRWV : 85.75 (+8.05%)
VRTS : 159.06 (-2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 126.81
2nd Resistance Point 125.89
1st Resistance Point 124.25
Last Price 122.62
1st Support Level 121.69
2nd Support Level 120.77
3rd Support Level 119.13

See More

52-Week High 128.70
Last Price 122.62
Fibonacci 61.8% 113.37
Fibonacci 50% 108.63
Fibonacci 38.2% 103.90
52-Week Low 88.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar